There has been an explosion of newer HER2-directed therapies, including monoclonal antibodies, novel antibody-drug conjugates ...

A University of Kentucky Markey Cancer Center study reveals how prostate cancer cells adapt their metabolism to thrive in ...

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).

A woman planning for her last months makes an unusual request of her spouse in Ann Packer’s novel.

RAD 101 demonstrated significant tumor uptake and 92% concordance with MRI in a phase 2b trial, enhancing confidence in its diagnostic potential. The agent targets fatty acid synthase, aiding in ...

Mark Cuban drug firm adds cancer biosimilar Vegzelma to its marketplace for hospitals and healthcare providers at discounted prices.

Disclaimer: Trastuzumab deruxtecan has not been approved by the FDA for the neoadjuvant or adjuvant setting for early-stage, ...

Combination of Castle Biosciences’ DecisionDx-UM and PRAME show predicting outcomes in patients with uveal melanoma: Study: Friendswood, Texas Friday, December 19, 2025, 15:00 H ...

Researchers demonstrated that newly developed molecules designed to block an immune checkpoint can trigger a powerful immune response against tumors. Scientists at MIT and Stanford University have ...

What happens if PSA levels start rising after surgery or radiation for prostate cancer? Up to a third of men treated for the disease will eventually confront this problem. If there's no accompanying ...

NeOnc Technologies Holdings, Inc. ($NTHI) announced an update on their ongoing clinical study. Study Overview: NeOnc Technologies Holdings, Inc.

NANJING, China and GAITHERSBURG, Md., Dec. 18, 2025 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced that the new drug application for ...